Immunonutritional therapy in liver transplant patients - a randomised trial

Phase 3

Recruiting

• Conditions: End-stage liver disease; Other - Liver

• Registration Number: ACTRN12605000449639
• Lead Sponsor: Dr Lindsay Plank

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-21
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Listed for elective liver transplantation; written informed consent.

Exclusion Criteria

Re-transplant, acute liver failure, pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in total body protein, measured by neutron activation analysis, over the preoperative period of supplementation.[Study entry to transplant]

Secondary Outcome Measures

Name	Time	Method
Physiologic function over the preoperative period.[Study entry to transplant];Total body protein and physiologic function[Measured at 10, 30, 90, 180 and 360 days post-transplant.];Health-related quality of life[Measured at baseline and 6 and 12 months post-transplant.];Infectious complications[Within first 30 postoperative days.];Immune status[Measured at baseline and day of transplant];Inflammatory markers and GH/IGF axis[At baseline, immediately pre-transplant, and on day 10 post-transplant.]